logo
ProjectEnded

EUbOPEN: Enabling and Unlocking biology in the OPEN

Sector: Hospital • Location: Germany, United Kingdom, Sweden, Netherlands, Switzerland, United States, Canada, France

Source: EU Funding & Tenders Portal

The EUbOPEN partnership of excellence will aim to generate the largest freely available set of high-quality chemical inhibitors for human proteins. These compounds will include chemical probes for solute carriers (SLCs), E3-ubiquitin ligases (E3s) and other proteins, and a chemogenomic library (CGL) of 3000-5000 compounds covering one third of the druggable genome. All compounds in the sets will b

Status
Closed
Sector
Hospital, Education, Electric Vehicles (EVs), Chemical (Industrial), Manufacturing (Industrial), Government, Automotive
Location
Germany
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about EUbOPEN: Enabling and Unlocking biology in the OPEN

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “EUbOPEN: Enabling and Unlocking biology in the OPEN” is an infrastructure initiative in the Hospital sector, located in Germany, United Kingdom, Sweden, Netherlands, Switzerland, United States, Canada, France. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Sponsoring Agency

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

The EUbOPEN partnership of excellence will aim to generate the largest freely available set of high-quality chemical inhibitors for human proteins. These compounds will include chemical probes for solute carriers (SLCs), E3-ubiquitin ligases (E3s) and other proteins, and a chemogenomic library (CGL) of 3000-5000 compounds covering one third of the druggable genome. All compounds in the sets will be comprehensively characterised defining their selectivity, potency and cellular activity. The compounds will be annotated with a series of established and novel biochemical and cell-based assays, including many derived from primary patient cells. Diseases of particular focus will be inflammatory bowel disease, cancer and neurodegeneration. EUbOPEN partners have proven track records leading large international open science projects, developing unencumbered key reagents, and exploring new target areas. A strong commitment to open data and open science will accelerate the dissemination of knowledge and reagents as well as mitigate ethical issues that might arise by working with patient-derived cells. EUbOPEN will partner extensively with other large projects (e.g. ReSOLUTE, Illuminating the Druggable Genome) to minimize duplication of effort and to maximize global coordination. EUbOPEN will provide via the EFPIA partners the public access to industry’s deep medicinal chemistry skills. Sustainability of the project’s resources will be ensured through already established partnerships with chemical vendors and cheminformatics/database providers, which will ensure the long-term availability of the new chemical tool sets, all associated profiling data and established protocols. The EUbOPEN project will form the foundation for future efforts to generate chemical modulators for the entire druggable genome and will develop new technologies significantly shortening hit and lead identification processes.

Location

Country

Germany

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital, Education, Electric Vehicles (EVs), Chemical (Industrial), Manufacturing (Industrial), Government, Automotive

Article published date

2025-12-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project